Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23021086 | 0.86 | GPR119 (0.35) | LMNAMAPTCYP2C9ALOX15CYP2C19 | |
| SCHEMBL22206969 | 0.79 | MAPT (0.44) | LMNAMAPTCYP2C9ALOX15CYP2C19 | |
| SCHEMBL22216336 | 0.79 | MAPT (0.44) | LMNAMAPTCYP2C9ALOX15CYP2C19 | |
| SCHEMBL22206970 | 0.79 | MAPT (0.44) | LMNAMAPTCYP2C9ALOX15CYP2C19 | |
| SCHEMBL23907169 | 0.76 | MAPT (0.53) | LMNAMAPTCYP2C9ALOX15CYP2C19 | |
| SCHEMBL23907181 | 0.76 | LMNA (0.49) | LMNAMAPTCYP2C9ALOX15CYP2C19 | |
| SCHEMBL22216404 | 0.76 | LMNA (0.49) | LMNAMAPTCYP2C9ALOX15CYP2C19 | |
| SCHEMBL23907167 | 0.76 | MAPT (0.53) | LMNAMAPTCYP2C9ALOX15CYP2C19 | |
| SCHEMBL22216285 | 0.76 | MAPT (0.53) | LMNAMAPTCYP2C9ALOX15CYP2C19 | |
| SCHEMBL22999615 | 0.72 | TP53 (0.47) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021032323-A1 | FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES | GALAPAGOS NV (BE) | 2021-02-25 | — | — | WO | disclosed |
| EP-3782997-A1 | FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES | Galapagos N.V. (BE) | 2021-02-24 | — | — | EP | disclosed |